-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January 7, 2021 // -- In a recent study published in the international journal Cell Host and Microbe entitled "Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease", scientists from Brown University and others in the United States have found that immunoglobulin A may target a specific microbiome substation in inflammatory bowel disease.
pathogenesis of inflammatory bowel disease (IBD, inflammatory bowel disease) is thought to be the result of a combination of host genetic factors and intestinal ecological imbalances, and previous studies of a small number of IBD patients have shown that inflammatory bacterial groups tend to be highly covered by the secretional immunoglobulin IgA.
Photo Source: pasmov.com In this study, researchers used bacterial fluorescence-activated cell sequencing technology in conjunction with 16S rRNA gene sequencing technology (IgA-SEQ) to analyze IGA coverage of gut microbes in the body of a larger queue of IBD patients, while also identifying specific bacteria associated with disease and therapy.
researchers found that 43 bacterial groups showed significantly higher levels of IGA coverage compared to the controls, eight of which showed different IgA coverage, but with similar abundance.
Compared to the control group, patients treated with anti-TNF-α therapy tended to exhibit significantly altered microbial-specific IgA responses;
addition, the research highlights of this paper include: 1) the researchers used IGA-SEQ technology to evaluate a large number of IBD patients with IgA-covered bacterial community; IBD-related bacterial community; 3) patients treated with anti-INF-α therapy were able to exhibit a specific IgA response to microbial changes; and 4) IgA-covered envelopes of bacteria belonging to the genus Vibrillobacteria were directly related to delays in surgery time in IBD patients.
() Original source: Jason M. Shapiro, Marcel R.de Zoete, Noah W.Palm, et al. Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease, Cell Host & Microbe (2020) doi:10.1016/j.chom.2020.12.003